Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADCT ADC Therapeutics	$3.47 -3.5%	$1.64	$1.05 ▼ $4.13	$343.65M	1.54	491,243 shs	866 shs
PRTA Prothena	$4.86 +4.3%	$8.54	$4.32 ▼ $25.42	$259.98M	0.11	692,020 shs	1.31 million shs
RCKT Rocket Pharmaceuticals	$3.00 +8.3%	$6.01	$2.19 ▼ $26.98	$316.09M	1.02	1.93 million shs	7.82 million shs
TELO Telomir Pharmaceuticals	$2.05 +0.5%	$2.54	$1.88 ▼ $8.40	$61.46M	-0.38	139,353 shs	356 shs

2025 Gold Forecast: A Perfect Storm for Demand

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADCT ADC Therapeutics	+2.66%	+43.80%	+148.79%	+110.85%	+8.45%
PRTA Prothena	+3.65%	+5.46%	-43.18%	-67.69%	-78.21%
RCKT Rocket Pharmaceuticals	+6.86%	+27.04%	-63.05%	-67.86%	-86.50%
TELO Telomir Pharmaceuticals	-2.86%	-2.86%	-21.24%	-50.61%	-64.71%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADCT ADC Therapeutics	2.3548 of 5 stars	3.5	2.0	0.0	3.4	0.8	0.6
PRTA Prothena	2.8491 of 5 stars	4.2	1.0	0.0	2.0	1.7	1.3
RCKT Rocket Pharmaceuticals	4.8269 of 5 stars	4.2	2.0	4.7	2.2	5.0	1.3
TELO Telomir Pharmaceuticals	2.5315 of 5 stars	3.8	1.0	0.0	3.2	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADCT ADC Therapeutics	3.00	Buy	$7.75	123.67% Upside
PRTA Prothena	2.33	Hold	$31.50	548.15% Upside
RCKT Rocket Pharmaceuticals	2.41	Hold	$19.57	552.38% Upside
TELO Telomir Pharmaceuticals	3.50	Strong Buy	$15.00	631.71% Upside

Current Analyst Ratings Breakdown

Latest TELO, RCKT, ADCT, and PRTA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/3/2025	RCKT Rocket Pharmaceuticals	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$34.00 ➝ $11.00
5/30/2025	RCKT Rocket Pharmaceuticals	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ In-Line	$5.00
5/28/2025	RCKT Rocket Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
5/28/2025	PRTA Prothena	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Underperform
5/28/2025	RCKT Rocket Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Neutral
5/28/2025	RCKT Rocket Pharmaceuticals	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$32.00 ➝ $9.00
5/28/2025	RCKT Rocket Pharmaceuticals	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$30.00 ➝ $8.00
5/28/2025	RCKT Rocket Pharmaceuticals	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Outperform ➝ Sector Outperform	$51.00 ➝ $19.00
5/28/2025	RCKT Rocket Pharmaceuticals	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Neutral ➝ Sell
5/28/2025	RCKT Rocket Pharmaceuticals	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform	$37.00 ➝ $8.00
5/28/2025	RCKT Rocket Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Equal Weight	$7.00

(Data available from 6/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADCT ADC Therapeutics	$75.82M	4.53	N/A	N/A	($1.93) per share	-1.80
PRTA Prothena	$137.94M	1.90	N/A	N/A	$10.46 per share	0.46
RCKT Rocket Pharmaceuticals	N/A	N/A	N/A	N/A	$5.46 per share	N/A
TELO Telomir Pharmaceuticals	N/A	N/A	N/A	N/A	$0.02 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADCT ADC Therapeutics	-$240.05M	-$1.45	N/A	N/A	N/A	-300.00%	N/A	-61.33%	8/5/2025 (Estimated)
PRTA Prothena	-$147.03M	-$2.08	N/A	N/A	N/A	-90.50%	-22.67%	-19.68%	8/14/2025 (Estimated)
RCKT Rocket Pharmaceuticals	-$245.60M	-$2.63	N/A	N/A	N/A	N/A	-62.62%	-54.17%	8/4/2025 (Estimated)
TELO Telomir Pharmaceuticals	-$16.53M	-$0.42	N/A	N/A	N/A	N/A	-1,170.58%	-832.67%	8/12/2025 (Estimated)

Latest TELO, RCKT, ADCT, and PRTA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	ADCT ADC Therapeutics	-$0.38	-$0.36	+$0.02	-$0.36	$17.71 million	$23.03 million
5/13/2025	Q1 2025	RCKT Rocket Pharmaceuticals	-$0.58	-$0.56	+$0.02	N/A	N/A	N/A
5/12/2025	Q1 2025	TELO Telomir Pharmaceuticals	-$0.10	-$0.07	+$0.03	-$0.07	N/A	N/A
5/8/2025	Q1 2025	PRTA Prothena	-$0.92	-$1.12	-$0.20	-$1.12	$8.18 million	$2.83 million
5/5/2025	Q1 2025	RCKT Rocket Pharmaceuticals	-$0.59	-$0.56	+$0.03	-$0.56	$0.80 million	N/A
3/27/2025	Q4 2024	ADCT ADC Therapeutics	-$0.35	-$0.29	+$0.06	-$0.29	$19.01 million	$19.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADCT ADC Therapeutics	N/A	N/A	N/A	N/A	N/A
PRTA Prothena	N/A	N/A	N/A	N/A	N/A
RCKT Rocket Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
TELO Telomir Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADCT ADC Therapeutics	N/A	4.92	4.68
PRTA Prothena	N/A	11.52	11.52
RCKT Rocket Pharmaceuticals	0.06	6.05	6.05
TELO Telomir Pharmaceuticals	N/A	1.94	1.94

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADCT ADC Therapeutics	41.10%
PRTA Prothena	97.08%
RCKT Rocket Pharmaceuticals	98.39%
TELO Telomir Pharmaceuticals	N/A

Insider Ownership

Company	Insider Ownership
ADCT ADC Therapeutics	4.10%
PRTA Prothena	9.20%
RCKT Rocket Pharmaceuticals	24.76%
TELO Telomir Pharmaceuticals	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADCT ADC Therapeutics	310	99.18 million	92.73 million	Optionable
PRTA Prothena	130	53.83 million	38.64 million	Optionable
RCKT Rocket Pharmaceuticals	240	106.79 million	65.18 million	Optionable
TELO Telomir Pharmaceuticals	1	29.76 million	N/A	N/A

TELO, RCKT, ADCT, and PRTA Headlines

Recent News About These Companies

Telomir announces positive preclinical data for its novel oral AMD therapeutic

June 3 at 8:21 AM | ophthalmologytimes.com

Telomir Pharmaceuticals Joins BIO Convention for Partnerships

June 2 at 8:35 AM | tipranks.com

Telomir Pharmaceuticals to Participate in BIO 2025 in Boston as Company Prepares for IND Submission and Advances Breakthrough Longevity Platform

June 2 at 8:30 AM | accessnewswire.com

Telomir Pharmaceuticals, Inc: Telomir Pharmaceuticals Confirms Telomir-1 Restores Vision and Retinal Structure in Age-Related Macular Degeneration Animal Model Using FDA ...

May 29, 2025 | finanznachrichten.de

TELO Produces Results with Exciting AMD Implications

May 29, 2025 | msn.com

Telomir Pharmaceuticals Confirms Telomir-1 Restores Vision and Retinal Structure in Age-Related Macular Degeneration (AMD) Animal Model Using FDA-Recognized Surrogate Endpoints

May 29, 2025 | accessnewswire.com

Telomir Pharmaceuticals CFO Michelle Yanez Leaves Company; Resignation Was a Mutual Separation

May 21, 2025 | marketwatch.com

Telomir Pharmaceuticals Appoints New Chief Financial Officer

May 21, 2025 | tipranks.com

Telomir Pharmaceuticals Secures $3 Million at a Premium in Straight Equity Sale Involving No Warrants to Advance Rare Disease IND

May 21, 2025 | accessnewswire.com

Telomir Pharmaceuticals

May 19, 2025 | thepharmaletter.com

Telomir unveils new drug candidate against resistant bacteria

May 16, 2025 | investing.com

Telomir Pharma touts breakthrough in drug-resistant infections

May 16, 2025 | thepharmaletter.com

TELO Announces Exciting Discovery

May 15, 2025 | msn.com

Telomir Pharmaceuticals Adds Telomir-Ag2 as a Novel Drug Candidate to Pipeline Following Breakthrough Efficacy Against MARSA and Drug-Resistant Infections, Targeting a $30B+ Antimicrobial Market Opportunity

May 15, 2025 | accessnewswire.com

TELO Announces Promising Aging Reversal Test Results

May 8, 2025 | msn.com

Telomir Pharmaceuticals Unveils Promising Preclinical Data on Telomir-1

May 7, 2025 | tipranks.com

Telomir Pharmaceuticals (TELO) Projected to Post Earnings on Monday

May 7, 2025 | marketbeat.com

Telomir Pharmaceuticals Demonstrates Telomir-1 Reverses Key Drivers of Cellular Decline in Human Cell Lines Supporting Therapeutic Potential in Autism and Spasmodic Dysphonia

May 7, 2025 | accessnewswire.com

Why Telomir Pharmaceuticals, Inc.’s (TELO) Stock Is Up 6.57%

May 3, 2025 | aaii.com

Why Telomir Pharmaceuticals, Inc.’s (TELO) Stock Is Down 7.25%

April 29, 2025 | aaii.com

Why Telomir Pharmaceuticals, Inc.’s (TELO) Stock Is Up 10.93%

April 2, 2025 | aaii.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

TELO, RCKT, ADCT, and PRTA Company Descriptions

ADC Therapeutics NYSE:ADCT

$3.46 -0.13 (-3.48%)

As of 09:33 AM Eastern

ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound, ADCT-602 that is in a Phase 1/2 investigator-initiated study in relapsed or refractory B-cell acute lymphoblastic leukemia. Further, its clinical-stage pipeline consists of ADCT-601 (mipasetamab uzoptirine) targeting AXL as a single agent and/or in combination in sarcoma, pancreatic, and NSCLC, as well as pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, and other undisclosed targets. The company was incorporated in 2011 and is headquartered in Epalinges, Switzerland.

Prothena NASDAQ:PRTA

$4.86 +0.20 (+4.29%)

As of 09:33 AM Eastern

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX123, a dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease; and PRX019 for the treatment of neurogenerative diseases, as well as TDP-43 for the treatment of amyotrophic lateral sclerosis. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and a collaboration agreement with Bristol-Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. The company was incorporated in 2012 and is based in Dublin, Ireland.

Rocket Pharmaceuticals NASDAQ:RCKT

$3.00 +0.23 (+8.30%)

As of 09:33 AM Eastern

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy, an inheritable cardiac disorder; and BAG3 Dilated Cardiomyopathy. It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey.

Telomir Pharmaceuticals NASDAQ:TELO

$2.05 +0.01 (+0.49%)

As of 09:33 AM Eastern

Telomir Pharmaceuticals, Inc., a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. The company develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy health problems. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. in October 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Baltimore, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time